Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06197672 · ClinicalTrials.gov registry record · Phase 1
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
A Phase 1 study of Acute Myeloid Leukemia, sponsored by Huda Salman.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06197672 is a Phase 1 study of Acute Myeloid Leukemia that is actively recruiting participants, run by Huda Salman. The registered enrollment target is 30 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06197672, a Phase 1 study of Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Huda Salman.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.
Conditions Studied
Interventions
- BIOLOGICAL CD4CAR
Study Locations (4)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Riley Hospital for Children - Indianapolis
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2042-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06197672
The ClinicalTrials.gov registry entry for NCT06197672 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The listed sponsor is Huda Salman, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CD4CAR is the first listed.
NCT06197672 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06197672 about?
NCT06197672 is a clinical study titled "Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant". This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient population and also the presence of efficacy signal de...
What is the current status of trial NCT06197672?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-03-19. Estimated completion is 2042-12-31.
What conditions does trial NCT06197672 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT06197672?
The interventions under investigation include: CD4CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT06197672?
This trial is sponsored by Huda Salman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06197672 being conducted?
This trial has 4 study locations across Florida, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.